Full Breakdown
Researchers Test Abortion-Related Drugs for Breast-Cancer Prevention Amid U.S. Political Pushback
By Drooid · · How we work
New Research on Anti-Progesterone Drugs
Scientists in the United Kingdom are evaluating whether drugs used for medical abortion—mifepristone and ulipristal acetate (UPA, marketed as Ella)—can lower breast-cancer risk. In a study led by oncologist Dr. Sacha Howell at the University of Manchester, 24 pre-menopausal women with a family history of breast cancer took a daily dose of UPA for three months. Breast biopsies and MRI scans before and after treatment showed fewer and less active cells thought to give rise to aggressive cancers, and a reduction in tissue density that may diminish mutation-promoting signals.
Background and Context
Anti-progesterone agents have been prescribed for uterine fibroids and endometriosis. By blocking progesterone, which drives breast-cell proliferation, investigators see a possible preventive role in oncology. The United Kingdom and other European nations continue these trials with government backing, while the United States has slowed after anti-abortion groups targeted UPA following its 2010 emergency-contraceptive approval and a 2023 study linking higher doses to medication abortion.
Key Figures and Groups
- Dr. Sacha Howell – Oncologist, University of Manchester; leads the UPA trial.
- Dr. Bruno Simoes – University of Manchester; collaborator on cell-visualization work.
- Dr. Laura Esserman – Breast-cancer surgeon, UCSF; warns political pressure hampers U.S. research.
- Wendy Wright – Concerned Women for America; frames UPA as an abortion drug.
- Pamela Cachart – Trial participant; joined after losing her mother to breast cancer.
- Mary Benjamin – Triple-negative breast-cancer survivor; opposes abortion rights but supports scientific study.
Data and Statistics
- The Manchester trial enrolled 24 women who each received UPA for 12 weeks.
- Researchers reported a reduction in both the number and activity of potentially cancer-causing cells.
- Breast tissue density decreased, a factor linked to lower mutation risk.
- A separate UK mammography study cited by Dr. Howell found about eight cancers per 1,000 screened women, highlighting detection challenges in dense breasts.
Why It Matters
If anti-progesterone drugs can reliably lower breast-cancer incidence, the public-health impact could be substantial. Dr. Esserman noted that halving the U.S. burden of roughly 325,000 annual cases would cut cases to about 150,000, reducing mortality and treatment costs. Lower density could also improve mammographic detection.
Official Statements and Responses
- Dr. Howell called for clear FDA guidance and administrative support to encourage further trials.
- Wendy Wright of Concerned Women for America asserted that UPA is “an abortion drug” and warned it “may end up harming women.”
On-the-Ground Perspectives
Trial participant Pamela Cachart described joining the study as a way to “pay it forward.” She said the medication made her breast tissue feel “relaxed,” which she believes could lower her own risk.
Conflicting Reports and Gaps
U.S. trial data for UPA in breast-cancer prevention are lacking, leaving uncertainty about how the drug’s effects translate across populations and regulatory environments. European studies suggest safety and efficacy, but the absence of comparable American research creates questions about FDA pathways and long-term outcomes.
*This article synthesizes reporting from PBS NewsHour’s “Beyond Abortion” series, featuring correspondent Sarah Varney’s investigation in the United Kingdom and commentary from U.S. experts.*
